recombinant interleukin-12

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

Interleukin-12 in Treating Patients With Multiple Myeloma

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Interleukin-12 in Treating Patients With Advanced Cancer

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma